business communications review |
||||
|
business communications review News for 19-Jan-25 Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General |
The Best business communications review websiteAll the business communications review information you need to know about is right
here. Presented and researched by http://www.mdnewscast.net. We've searched
the information super highway far and wide to provide you with the
best business communications review site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
business communications review
Although our site may not be of the same high quality of the site listed above, we believe that given time this business communications review site will be one of the major business communications review sites on the internet. After all we are relatively new to the e-commerce industry and are striving to reach perfection. Personally I have my doubts about whether we'll succeed. These business communications review websites are easily the very best that you will ever come across. In fact you could do what we did and search the Internet by day and by night without coming across something across something that meets your needs better. So I guess that you had better click on one of the hyperlinks and leave us behind. Come back again one day though, because we're improving the level of business communications review information every day. business communications review
If you are truly interested in the very best in business communications review then be sure you click the link above. We have researched the business communications review subject extensively and can guarantee that the people have the best. The business communications review links on the left side of this page will take you directly to the specific item you need so look around. We have made it easy for you and of course this company stands behind their business communications review with total satisfaction guarantees. New Findings on the Role of Glutathione in Cancer by: Priya F Shah
Cancer cells and normal cells are known to respond differently to nutrients and drugs that affect glutathione status. Numerous studies have shown that tumor cells have elevated levels of glutathione levels, which confers resistance to chemotherapy drugs. One of the challenges of cancer therapy is how to deplete tumor cells of glutathione, so as to make them more vulnerable to the effects of chemotherapy drugs, while at the same time allowing normal cells to remain relatively unaffected by chemotherapeutic drugs. A number of new findings have emerged that take into consideration the role of glutathione in pathways that promote programmed cell death (apoptosis) in cancer cells. A German study has reported that glutathione (GSH) plays a critical role in cellular mechanisms that result in cell death. The study found that cancer cells resistant to apoptosis had higher intracellular GSH levels. Depletion of glutathione in these tumor cells made them more vulnerable to the effects of anticancer drugs or the gene that promotes apoptosis (CD95 or APO-1/Fas). The researchers concluded that apoptosis resistance in tumor cells depends, at least in part, on intracellular GSH levels. (1) In another study conducted in Spain, researchers found that lowering GSH concentration may be convenient not only for the efficiency of chemotherapy, but also to induce a rather fast and direct apoptosis mechanism in tumor cells. (2) Based on that premise that the glutathione-S-transferase enzyme is expressed at high levels in many tumors, researchers at the Fox Chase Cancer Center in Pennsylvania, went on to design a novel prodrug (PABA/NO). The glutathione-s-transferase in tumor cells converts PABA/NO to lethal nitric oxide, resulting in death of the tumor cell. The prodrug was shown to have antitumor effects in an animal model for human ovarian cancer. (3) In the fourth study, Polish researchers found that ingesting a selenium supplement is beneficial, as a supportive element in chemotherapy. (4) Selenium is a co-factor of the enzyme glutathione peroxidase [GSH-P(x)] and was found to significantly increase the activity of GSH-P(x) in patients reciving the supplement. A previous clinical study by the same researchers recommended the administration of selenium in patients with ovarian cancer undergoing multi-drug chemotherapy. (5) Another interesting study by researchers in Texas showed that your chances of surviving a type of brain cancer, called primary malignant glioma, could depend on the type of glutathione-s-transferase (GST) gene you were born with. Having a combination of a two specific variants of GST (germ-line GSTP1*A/*A and GSTM1 null genotype) confers a survival advantage in some types of brain cancers, but also comes with an increased risk of adverse events related to chemotherapy. (6) There is compelling evidence to suggest a crucial role for glutathione and substances that target glutathione metabolism in the prevention and treatment of cancer. Undenatured whey protein is one of the natural foods known to selectively deplete cancer cells of their glutathione, thus making them more susceptible to such cancer treatments as radiation and chemotherapy. For a complete report on the research on undenatured whey protein and cancer see the report Glutathione (GSH) and Whey Protein in Cancer. http://www.1whey2health.com/cancer_glutathione.htm Disclaimer: The information here is not provided by medical professionals and is not intended as a substitute for medical advice. Please consult your physician before beginning any course of treatment. References: 1. Friesen C et al. [Cell Death and Differentiation advance online publication, 23 April 2004] 2. Tormos C et al. [Cancer Lett. 2004 May 10;208(1):103-13.] 3. Findlay VJ et al. [Mol Pharmacol. 2004 May;65(5):1070-9.] 4. Sieja K et al. [Gynecol Oncol. 2004 May;93(2):320-327.] 5. Sieja K. [Pharmazie. 1998 Jul;53(7):473-6.] 6. Okcu MF et. al. [Clin Cancer Res. 2004 Apr 15;10(8):2618-25.] Copyright © 2004 Priya Shah
|
|||
|
http://www.medmeet.com/ |
||||
| MD Meetings Medical Newscast Go Antiques |